Radiopharmaceutical Identity, Dose, and Route of Administration
| Protocol | Sestamibi or tetrofosmin | Imaging time |
| 1-d rest/stress | 8–12 mCi rest/24–36 mCi stress | 30–45 or 15–45 min (latter if pharmacologic stress) |
| 1-d stress/rest | 8–12 mCi stress/24–26 mCi rest | 15–45 or 30–45 min (latter if pharmacologic stress) |
| 2-d | 24–36 mCi for rest and stress | 30–45 or 15–45 min (latter if pharmacologic stress) |
| Dual-isotope | 2.5–4 mCi 201Tl rest/24–36 mCi 99mTc-labeled agents | 10–15 or 15–45 min (latter if pharmacologic stress) |
| 201Tl stress/rest | 2.5–4 mCi 201Tl stress | Within 10–15 min/3, 4, 24 h |
| 201Tl stress/rest reinjection | 2.5–4 mCi 201Tl stress/1–2 mCi rest | Within 10–15 min/3, 4, 24 h |
| Viability only | 3−4 mCi 201Tl rest | Within 10–15 min/4, 6, 24 h |
1 mCi = 37 MBq.
There should always be 1:3 ratio between activity of first dose and activity of second dose (e.g., 8-mCi first dose followed by 24-mCi second dose). In dual-isotope imaging, resting 201Tl study must be performed first.